Here we demonstrate a therapeutic window whereby targeting the BMP pathway together with BCR::ABL1 and SFKs in CML is more effective than targeting BCR::ABL1 alone, both in 2D and 3D culture. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.